investors & media
NASDAQ: (common stock)
Copyright West LLC. Minimum 15 minutes delayed.
Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free at up to Five Years of Follow-up CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 18, 2019-- bluebird bio, Inc.Read more
Data Include Updates from Phase 2/3 Starbeam Study (ALD-102) of Lenti-D for CALD and Ongoing Observational Study (ALD-103) of Allogeneic Hematopoietic Stem Cell Transplant for CALD CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) announced that updated data fromRead more
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 22, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in September: Citi 14 th Annual Biotech Conference , Wednesday, September 4 , at 8:00 a.m.Read more